Clinical trials: Diffuse Interstitial Lung Disease
Systemic Sclerosis Pulmonary, Pulmonary Hypertension
Infusion of Allogeneic Mesenchymal Stem Cells in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmonary Involvement
Progressive SSc is an entity with limited therapeutic alternatives and with asurvival rate of less than 45% in the first 3 to 5 years.
- Conditions
- Systemic Sclerosis Pulmonary, Pulmonary Hypertension, Pulmonary Fibrosis
- Trial name
- NCT04432545
- Testing
- Mesenchymal Stem Cells from Wharton ́s jellyintravenous infusion of Mesenchymal Stem Cells from Wharton ́s jelly
- Where
- Colombia
- Sponsor
- Universidad de la Sabana
Scleroderma
Morbidity and Mortality Follow Up for the Scleroderma Lung Study
The primary intent of this study is to add to the body of knowledge on scleroderma patients with interstitial lung disease. While lung disease is recognized as the leading cause of death amongst patients with scleroderma, there…
- Trial name
- NCT01762449
- Testing
- Followup survey
- Volunteers
- 158 people
- Sponsor
- Duke University
Transbronchial Cryobiopsy, Freezing Time
The Diagnostic Yield and Safety of Transbronchial Cryobiopsy in Different Freezing Time in the Diffuse Parenchymal Lung Diseases
Transbronchial cryobiopsy in different freezing time is performed in patients with undefined diffuse parenchymal lung diseases, and assess the diagnostic yield and safety.
- Conditions
- Transbronchial Cryobiopsy, Freezing Time, Diagnostic Yield, Safety
- Trial name
- NCT03927235
- Testing
- Transbronchial Cryobiopsy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Race, Ethnicity, and Diffuse Parenchymal Lung Disease
The purpose of this study is to identify factors that contribute to higher mortality rates among blacks and Hispanics with diffuse parenchymal lung disease.
- Conditions
- Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Diffuse Parenchymal Lung Disease
- Trial name
- NCT00453713
- Where
- United States
- Volunteers
- 565 people
- Sponsor
- Columbia University
Diffuse Parenchymal Lung Diseases
Validation of Alveolar Probe-based Confocal Laser Endomicroscopy Descriptors in Diffuse Parenchymal Lung Diseases
Diffuse parenchymal lung diseases (DPLD) include a variety of respiratory conditions that affect either the pulmonary interstitium or the alveolar space .
- Trial name
- Microsemio-PI (NCT02961335)
- Testing
- Bronchoscopy, Confocal microendoscopy, Biopsy sampling
- Where
- France
- Volunteers
- 38 people
- Sponsor
- University Hospital, Rouen
Interstitial Lung Disease, Scleroderma
Rituxmab Versus IL-6 in Treating ILD
All SSc patients should know if they have been diagnosed with interstitial lung disease, or pulmonary hypertension and keep results from his/her last pulmonary function test, chest imaging, echocardiogram and stress test
- Trial name
- NCT05963048
- Testing
- Rituximab, IL6 inhibitor
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Assiut University
Systemic Sclerosis, Scleroderma
A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients
The purpose of this research study is to learn about the effects of the medication ixazomib in participants with scleroderma/systemic sclerosis including its safety and tolerability, its effects on skin, lungs and other organs…
- Conditions
- Systemic Sclerosis, Scleroderma, Diffuse Systemic Sclerosis, Diffuse Scleroderma
- Trial name
- NCT04837131
- Testing
- Ixazomib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Michael M. Pham
Inspiration Expiration Thoracic TDM Sequences of Patients With Diffuse Interstitial Lung Disease (DIP)
Digital Modeling of Thoracic CT and Pulmonary Fibrosis
Currently, to our knowledge, there is little data on the combination of tools based on a similar concept to understand and evaluate ILDs.
- Trial name
- MLQ-CT (NCT06618924)
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Interstitial Lung Disease
Diagnostic Value of Transbronchial Lung Cryobiopsy
Evaluating the diagnostic value of transbronchial lung cryobiopsy (TBLC) as well as its procedural feasibility and safety in a prospective series of 20 patients with diffuse interstitial lung diseases (DILD) who are referred for…
- Trial name
- NCT02579304
- Testing
- transbronchial lung cryobiopsy
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- KU Leuven
Osteoporosis, Interstitial Lung Disease
Opportunistic Screening for Osteoporotic Vertebral Fractures in Patients With Diffuse Interstitial Lung Disease
It is well known that some chronic respiratory pathologies such as asthma or chronic obstructive pulmonary disease (COPD) are associated with an increased risk of osteoporosis, due to the pathology itself and the therapies…
- Conditions
- Osteoporosis, Interstitial Lung Disease, Vertebral Fracture
- Trial name
- NCT05714787
- Testing
- Chest CT Scan examination
- Where
- France
- Volunteers
- 202 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Interstitial Lung Disease, Connective Tissue Disease
A Clinical Trial for CTD-ILD Treatment
The first objective of this protocol is to assess the tolerability and safety of N-acetylcysteine (NAC) in patients with connective tissue disease related interstitial lung disease (CTD-ILD).
- Trial name
- NCT01424033
- Testing
- N-Acetylcysteine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Michigan
Diffuse Parenchymal Lung Diseases
Fibered Confocal Fluorescence Microscopy Imaging in Patients With Diffuse Parenchymal Lung Diseases
Fibered confocal fluorescence microscopy (FCFM) (CellvizioR Lung, MaunaKea Technologies, France) could potentially provide diagnostic information on fibrosis and inflammation of the distal air spaces associated with diffuse…
- Trial name
- NCT01624753
- Testing
- confocal microscopy
- Where
- Singapore
- Volunteers
- 27 people
- Sponsor
- Singapore General Hospital
Systemic Sclerosis Pulmonary, Pulmonary Hypertension
Infusion of Allogeneic Stromal Mesenchymal Stem Cells From Wharton´s Jelly in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmonary Involvement to Treatment
Progressive SSc is an entity with limited therapeutic alternatives and a survival rate of less than 45% within the first 3 to 5 years.
- Conditions
- Systemic Sclerosis Pulmonary, Pulmonary Hypertension, Pulmonary Fibrosis
- Trial name
- NCT07542067
- Testing
- Mesenchymal Stem Cells from Wharton´s jelly
- Where
- Colombia
- Volunteers
- 1 people
- Sponsor
- Fundación Neumologica Colombiana
Lung Diseases, Pulmonary Fibrosis
Diffuse Fibrotic Lung Disease
To determine the effects of cyclophosphamide compared with prednisone, dapsone, or high-dose intermittent 'pulse' therapy with methylprednisolone in patients with idiopathic pulmonary fibrosis.
- Conditions
- Lung Diseases, Pulmonary Fibrosis, Sarcoidosis
- Trial name
- NCT00000596
- Testing
- prednisone, cyclophosphamide, dapsone
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Systemic Sclerosis (SSc), Scleroderma
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 24 weeks (Period 1) in adult participants with systemic sclerosis, followed by an open-label…
- Trial name
- NCT06843239
- Testing
- Tibulizumab
- Where
- 60 sites in United States, Argentina and 8 more
- Volunteers
- 80 people
- Sponsor
- Zura Bio Inc
Lung Diseases, Interstitial, Systemic Sclerosis
Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis
The purpose of this study is to look at whether bortezomib, mycophenolate or the combination of both is better to treat scarring of the lung caused by Systemic Sclerosis.
- Conditions
- Lung Diseases, Interstitial, Systemic Sclerosis, Scleroderma
- Trial name
- NCT02370693
- Testing
- Bortezomib, Mycophenolate mofetil
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Northwestern University
Diffuse Parenchymal Lung Diseases
The Diagnostic Yield and Safety of Transbronchial Cryobiopsy in Diffuse Parenchymal Lung Diseases
The Diagnostic yield and Safety of transbronchial cryobiopsy in the diagnosis of diffuse parenchymal lung diseases are investigated in this multicenter, prospective and real world study.
- Trial name
- NCT03704233
- Testing
- Transbronchial cryobiopsy
- Where
- 26 sites in China
- Volunteers
- 350 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Interstitial Lung Disease Due to Systemic Disease (Disorder), Interstitial Lung Disease in Patients With Rheumatoid Arthritis
Physical Exercise Program for Adults With Diffuse Interstitial Lung Disease in a Pulmonary Rehabilitation Context
This study aims to evaluate the effectiveness of an exercise program that includes three exercise modalities (Aerobic, Limb Strength and Respiratory Muscle Strength) versus an exercise program that includes only one modality…
- Conditions
- Interstitial Lung Disease Due to Systemic Disease (Disorder), Interstitial Lung Disease in Patients With Rheumatoid Arthritis, Pulmonary Fibrosis
- Trial name
- NCT07061873
- Testing
- Aerobic excersise, Muscle strength limbs, inspiratory muscle strength
- Where
- Chile
- Volunteers
- 29 people
- Sponsor
- Universidad de La Frontera
Rheumatoid Arthritis, Ankylosing Spondylitis
PatientSpot Formerly Known as ArthritisPower
Patient Power is a patient research network and database (registry) to collect prospective information about demographics, self-reported diagnoses and medications, and willingness to participate in research from participants with…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout
- Trial name
- NCT03840928
- Where
- United States
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Global Healthy Living Foundation
Idiopathic Interstitial Pneumopathy/Pneumopathy Interstitial Diffuse, Paediatric and Adult Patients
RaDiCo PID Cohort (RaDiCo-ILD Cohort in English)
The main objective is to describe the phenotypic features of the paediatric and adult patients with Idiopathic Interstitial Pneumopathy/Pneumopathy Interstitial Diffuse (IIP/PID), at diagnosis and during the follow-up.
- Trial name
- RaDiCo-PID (NCT04238871)
- Where
- 2 sites in France
- Volunteers
- 1,600 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France